Skip to content
10-K

Annual Report

CRESCENT BIOPHARMA, INC. CBIO

0001558370-25-000948

← back to feed
Filed
Feb 13, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 7, 2025 64.51M sh
Shares Diluted FY 2024 · Dec 31, 2024 64.48M sh
Shares Diluted FY 2024 · Dec 31, 2023 63.34M sh
Capex FY 2024 · Dec 31, 2024 $9.97K
Capex FY 2024 · Dec 31, 2023 $21.39K
Operating Cash Flow FY 2024 · Dec 31, 2024 −$31.1M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$34.88M
Eps Diluted FY 2024 · Dec 31, 2024 −$0.59
Eps Diluted FY 2024 · Dec 31, 2023 −$0.58
Eps Basic FY 2024 · Dec 31, 2024 −$0.59
Eps Basic FY 2024 · Dec 31, 2023 −$0.58
Rd Expense FY 2024 · Dec 31, 2024 $14.26M
Rd Expense FY 2024 · Dec 31, 2023 $20.07M
Net Income FY 2024 · Dec 31, 2024 −$37.88M
Net Income FY 2024 · Dec 31, 2023 −$36.9M
Operating Income FY 2024 · Dec 31, 2024 −$40.04M
Operating Income FY 2024 · Dec 31, 2023 −$39.28M
Cash And Equivalents FY 2024 · Dec 31, 2023 $41.79M
Stockholders Equity FY 2024 · Dec 31, 2023 $38.41M
Stockholders Equity FY 2024 · Dec 31, 2022 $42.93M
Current Liabilities FY 2024 · Dec 31, 2023 $6.84M
Total Liabilities FY 2024 · Dec 31, 2023 $6.9M
Current Assets FY 2024 · Dec 31, 2023 $43.79M
Total Assets FY 2024 · Dec 31, 2023 $45.32M